These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. Dousa KM; Kurz SG; Taracila MA; Bonfield T; Bethel CR; Barnes MD; Selvaraju S; Abdelhamed AM; Kreiswirth BN; Boom WH; Kasperbauer SH; Daley CL; Bonomo RA Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32393499 [No Abstract] [Full Text] [Related]
9. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335 [TBL] [Abstract][Full Text] [Related]
10. Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease. Negatu DA; Zimmerman MD; Dartois V; Dick T Antimicrob Agents Chemother; 2022 Sep; 66(9):e0079022. PubMed ID: 36047786 [TBL] [Abstract][Full Text] [Related]
11. Case Commentary: Dual β-lactam as part of regimen to treat Lippincott CK; Lamichhane G Antimicrob Agents Chemother; 2024 Jul; 68(7):e0058524. PubMed ID: 38837394 [TBL] [Abstract][Full Text] [Related]
12. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. van Ingen J; Totten SE; Helstrom NK; Heifets LB; Boeree MJ; Daley CL Antimicrob Agents Chemother; 2012 Dec; 56(12):6324-7. PubMed ID: 23027189 [TBL] [Abstract][Full Text] [Related]
13. [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline]. Wagner D; Lange C Dtsch Med Wochenschr; 2020 Aug; 145(16):1145-1151. PubMed ID: 32791550 [TBL] [Abstract][Full Text] [Related]
14. "One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Nguyen DC; Dousa KM; Kurz SG; Brown ST; Drusano G; Holland SM; Kreiswirth BN; Boom WH; Daley CL; Bonomo RA Clin Infect Dis; 2021 Oct; 73(8):1532-1536. PubMed ID: 34113990 [TBL] [Abstract][Full Text] [Related]
15. The role of amikacin in the treatment of nontuberculous mycobacterial disease. Raaijmakers J; Schildkraut JA; Hoefsloot W; van Ingen J Expert Opin Pharmacother; 2021 Oct; 22(15):1961-1974. PubMed ID: 34292097 [No Abstract] [Full Text] [Related]